Study identifier:D5252M00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I, randomized, open-label, 5-way crossover, single centre study in healthy subjects to assess the lung deposition of inhaled budesonide delivered via different inhalation devices
Healthy Volunteers
Phase 1
Yes
Pulmicort pMDI HFA, Budesonide pMDI HFA, Pulmicort Repulses, Pulmicort Turbohaler
All
16
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Pulmicort pMDI | Drug: Pulmicort pMDI HFA Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
Experimental: 2 Budesonide pMDI | Drug: Budesonide pMDI HFA Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
Experimental: 3 Budesonide pMDI + Aerochamber Zero-stat spacer | Drug: Budesonide pMDI HFA Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
Experimental: 4 Pulmicort repulses via Spira Nebuliser | Drug: Pulmicort Repulses Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations |
Experimental: 5 Pulmicort Turbohaler | Drug: Pulmicort Turbohaler Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |